web analytics
20.8 C
Munich
Wednesday, June 29, 2022

The Inside Scoop on Lucid Inc (OTCMKTS: LCDX)

Lucid Inc (OTCMKTS: LCDX) has seen an explosive move up the charts in recent weeks off its $0.50 base to recent highs near $3 per share. The stock has seen a huge rise in volume and has transformed into a volume leader in small caps.

LCDX is a medical device Company that has not put out a press release in years and is listed as DARK/DEFUNCT on Otc Markets Group website. The stock is seeing significant action as investors think they are buying EV stock Lucid Moters when they are not.

Lucid Inc (OTCMKTS: LCDX) is a medical device company that develops, manufactures, markets and sells point-of-care cellular imaging systems. Our patented and FDA-cleared VivaScope® technology provides physicians with real-time images of the epidermis and superficial dermis of the skin, as well as other epithelial tissues at a cellular level that can be interpreted by the physician at the bedside and/or transferred securely to a pathologist on VivaNet®, our HIPAA-compliant private telepathology network for remote diagnosis. With sensitivity and specificity that can rival the current “gold standard”, clinical histopathology (illustrated below right), but without all of the associated costs of a traditional biopsy, our platform imaging technology has the potential to significantly improve patient outcomes while simultaneously reducing costs. The Company has not filed a report in years and is listed as DARK/DEFUNCT on OtcMarkts Group website.

LCDX core products are FDA 510(k) cleared for clinical use and have regulatory approvals in most major markets. Our technology is already in use by physicians and researchers at major academic hospitals, and by pharmaceutical and cosmetic companies across the globe. Our devices allow these researchers to quickly and efficiently study the efficacy of new products, test ingredients, validate claims and determine safety. The technology is protected by 78 issued or pending patents worldwide.

To Find out the inside Scoop on LCDX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

LCDX

To date, its proprietary platform imaging technology has been the subject of more than 350 independently sponsored studies or publications spanning numerous clinical and research fields. Extensive research has been conducted in dermatologic disorders including melanoma and nonmelanoma skin cancers, dermatoses, inflammatory and pigmentation disorders. Additionally, the technology has been used to noninvasively study burns, wound healing, neuropathy and oral tissues. Ex-vivo research has been conducted in head and neck, breast biopsy and surgical specimens. Our in-vivo products are ideal for applications in which a traditional biopsy is counterproductive, such as validating the diagnosis of benign lesions (thus, reducing unnecessary biopsies), monitoring noninvasive therapies and determining product efficacy. In the future, the technology may be used to perform real-time pathology in the operating room on tissues removed from the body and to identify tissues in the body during surgery.

LCDX is an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation, from which we are currently exempt as a smaller reporting company, and stockholder approval of any golden parachute payments not previously approved in connection with a transaction resulting in a change of control. We expect to take advantage of these exemptions. Some investors may find our common stock less attractive as a result of our utilization of these exemptions, which may result in a less active trading market for our common stock and a more volatile stock price.

We have a Monster Pick Coming. Subscribe Right Now!

Currently moving up the charts LCDX  is a medical device Company that has not put out a press release in years and is listed as DARK/DEFUNCT on Otc Markets Group website. The stock is seeing significant action as investors think they are buying EV stock Lucid Moters when they are not. This case of mistaken identity is nothing new and happend notably with ZOON and Twitter in the past. We will be updating on LCDX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with LCDX.

WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?

Disclosure: we hold no position in LCDX either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.